TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.15%(-0.00100) 1D
Oct 13, 8:03:08 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
191.94M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
191.94M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
News stories
From web sources and news partners
ChartMill
·
1 hour ago
Discover which dow jones stocks are making waves on Tuesday.
Yahoo Finance
·
28 minutes ago
Tech Stocks Are Crushing the Market, but There's a Sneaky (and Dangerous) Risk for S&P 500 Investors
Seeking Alpha
·
56 minutes ago
Dealmaking volumes peaking in late-cycle classic (SP500:)
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA